Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Effective Income Tax Rate Reconciliation Tax Credits Research

Effective Income Tax Rate Reconciliation Tax Credits Research at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
0%0.0pp

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.

The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s effective income tax rate reconciliation tax credits research.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s effective income tax rate reconciliation tax credits research?
AbCellera Biologics Inc. (ABCL) reported effective income tax rate reconciliation tax credits research of -3.4% in Q4 2025.
What does effective income tax rate reconciliation tax credits research mean?
Represents the percentage point impact of research and development tax credits on the company's effective income tax rate. It highlights the relative importance of R&D incentives in lowering the overall tax burden compared to the statutory rate.